Nxera Pharma Co. Ltd, listed on the Tokio Stock Exchange, has entered into an exclusive licensing agreement with Santhera Pharmaceuticals under which Nxera will commercialize the drug AGAMREE® in Japan, South Korea, Australia and New Zealand. Concurrently, Nxera invests in SIX-listed Santhera Pharmaceuticals Holding AG.
Bär & Karrer acted as legal advisor to Nxera Pharma regarding the investment and Swiss law aspects of the license. The team was co-led by Luca Jagmetti (M&A) and Urs Kägi (Capital Markets) and included Oliver Brupbacher (Life Science), Markus Wang (IP), Matthias Tanner (Capital Markets) and Sebastian Sutter (M&A).
For further information please contact:
Media Relations, Eric Stupp Tel: +41 58 261 50 00
Email: eric.stupp@baerkarrer.ch
Bär & Karrer is a leading Swiss law firm with more than 200 lawyers, providing customized legal advice in complex transactions and litigation. Clients range from multinational corporations to private individuals in Switzerland and abroad. Bär & Karrer is present with offices in all main language regions in Switzerland and operates globally via an international network of leading law firms. For further information please visit baerkarrer.ch.
